Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Cladribine (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms CLARION
- Sponsors Merck KGaA
- 28 Aug 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).
- 21 May 2019 Status changed from not yet recruiting to recruiting.
- 13 Nov 2018 New trial record